乳腺癌放疗中容积调强弧形治疗与三维适形治疗诱发第二原发癌风险的批判性评估
该研究在20例早期乳腺癌患者中比较了两种容积调强弧形治疗(VMAT)布置与三维适形放疗(3D CRT)的剂量学及第二原发癌超额绝对风险(EAR)。结果显示,部分弧VMAT(VMAT_tang)对侧乳腺和对侧肺的EAR与3D CRT(FinF)相近,且同侧器官正常组织并发症概率(NTCP)更低;全弧VMAT(VMAT_full)的EAR最高。
要点
- VMAT_tang对侧乳腺EAR为2.4/万患者/年,与FinF的1.7相近。
- VMAT_full对侧乳腺EAR达8.5/万患者/年,显著高于FinF和VMAT_tang。
- FinF的同侧器官NTCP显著高于两种VMAT,VMAT_full毒性风险最低。
核心结论
- VMAT尤其是VMAT_tang对侧器官第二原发癌风险可能与3D CRT(FinF)相当,同时降低同侧器官急性和晚期NTCP。
- VMAT_full对侧器官第二原发癌风险较高。
研究设计与样本
- 在20例早期乳腺癌患者中,比较两种VMAT布置(VMAT_tang和VMAT_full)与3D CRT(FinF)计划。
- 使用Acuros剂量算法计算,处方剂量40.05 Gy分15次。
- 采用线性、线性指数、平台和全模型估算EAR,并计算NTCP。
主要发现
- 对侧乳腺EAR(最准确模型)在FinF、VMAT_tang和VMAT_full分别为1.7、2.4和8.5(每万患者每年)。
- 对侧肺EAR在FinF、VMAT_tang和VMAT_full分别为1.5、1.6和7.3(每万患者每年)。
- 所有分析终点的NTCP在FinF中显著高于两种VMAT,VMAT_full毒性风险最低。
关键数值与推荐
- 处方剂量为40.05 Gy分15次。
- 计划目标为最大化降低肺、对侧乳腺、心脏和冠状动脉剂量。
- 对侧乳腺EAR:FinF 1.7、VMAT_tang 2.4、VMAT_full 8.5(每万患者每年)。
- 对侧肺EAR:FinF 1.5、VMAT_tang 1.6、VMAT_full 7.3(每万患者每年)。
临床怎么用
- 对于早期乳腺癌放疗,VMAT_tang可能作为3D CRT的安全替代,兼顾第二原发癌风险和同侧器官毒性。
- 应避免使用VMAT_full以减少对侧器官第二原发癌风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the excess absolute risk (EAR) comparing volumetric modulated arc therapy (VMAT) and 3-dimensional (3D) conformal radiation therapy (CRT) in breast cancer radiation therapy treatment. METHODS AND MATERIALS: Two VMAT arrangements (VMAT_tang and VMAT_full, i.e. partial arcs with and without a sector of 0 Monitor Unit, respectively) and a 3D CRT (field-in-field [FinF]) plan were calculated with an accurate dose calculation algorithm, Acuros, in 20 patients presenting with early-stage breast cancer. The dose prescription was 40.05 Gy in 15 fractions. The planning aim was to maximize the dose reduction in the lungs, contralateral breast, heart, and coronary artery. EAR was estimated using different models: linear, linear-exponential, plateau, and full model, which better uses a carcinogenesis model and epidemiologic data for carcinoma induction and which accounts for cell repopulation or repair during the radiation therapy dose fractionation. EAR was computed for contralateral structures-breast and lung-as well as the ipsilateral lung. Normal tissue complication probability (NTCP) was computed to estimate the ipsilateral lung, heart, and skin toxicity, to balance with respect to second cancer induction. RESULTS: The planning objectives were fulfilled with all the planning techniques. EAR for contralateral breast carcinoma induction, estimated with the most accurate model, was 1.7, 2.4, and 8.5 (per 10,000 patients per year) with FinF, VMAT_tang, and VMAT_full, respectively. For the contralateral lung, these figures were 1.5, 1.6, and 7.3 (per 10,000 patients per year), respectively. NTCP for all the analyzed endpoints was significantly higher with FinF relative to both VMAT settings, with VMAT_full presenting the lowest toxicity risk. CONCLUSIONS: VMAT, in particular with the VMAT_tang setting, could have the same risk of second cancer induction as 3D CRT delivered with the FinF setting for the contralateral organs while reducing acute and late NTCP for the ipsilateral organs. VMAT might be considered a safe technique for breast cancer treatment for those aspects.
引用
- Fogliata A, De Rose F, Franceschini D, et al. Critical Appraisal of the Risk of Secondary Cancer Induction From Breast Radiation Therapy With Volumetric Modulated Arc Therapy Relative to 3D Conformal Therapy. Int J Radiat Oncol Biol Phys. 2017. PMID: 29249528. doi:10.1016/j.ijrobp.2017.10.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。